Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CALLISTO PHARMACEUTICALS INC (CLSP)
|
Add to portfolio |
|
|
|
| Price: |
$0.47
| | Metrics |
| OS: |
159.0
|
M
| |
|
|
| Market cap: |
$74.7
|
M
| |
|
|
|
Net cash:
|
|
| |
$0.00
|
per share
|
|
EV:
|
$74.7
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 |
| Revenues | 0.4 | 1.0 | 3.4 | 5.2 | 6.5 | 6.1 | 6.4 | 4.3 |
| Revenue growth | -64.2% | -70.0% | -34.0% | -20.3% | 6.1% | -4.6% | 48.6% | 215.8% |
| Cost of goods sold | 0.4 | 1.0 | 6.8 | 10.3 | 12.8 | 11.9 | 12.6 | 0.0 |
| Gross profit | 0.0 | 0.0 | -3.4 | -5.2 | -6.2 | -5.8 | -6.2 | 4.3 |
| Gross margin | 0.0% | 0.0% | -100.0% | -99.4% | -96.0% | -94.3% | -96.5% | 100.0% |
| Selling, general and administrative | | | | | | | | |
| Research and development | 13.3 | 9.6 | | | | | | |
| General and administrative | 7.6 | 7.3 | 5.1 | 4.6 | 4.3 | 6.4 | 5.9 | 3.6 |
| EBIT | -20.9 | -16.9 | -8.5 | -9.7 | -10.6 | -12.2 | -12.1 | -7.6 |
| EBIT margin | -5693.1% | -1650.9% | -249.2% | -187.7% | -162.3% | -198.3% | -187.6% | -176.8% |
| Pre-tax income | -15.3 | -33.6 | -18.4 | -9.7 | -7.9 | -12.9 | -11.8 | -7.5 |
| Income taxes | -8.5 | -7.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 55.6% | 23.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -6.8 | -25.8 | -20.2 | -9.7 | -20.9 | -15.3 | -11.8 | -7.5 |
| Net margin | -1847.9% | -2515.0% | -589.2% | -186.3% | -321.0% | -249.5% | -183.2% | -174.4% |
| |
| Diluted EPS | ($0.04) | ($0.37) | ($0.39) | ($0.20) | ($0.50) | ($0.40) | ($0.37) | ($0.26) |
| Shares outstanding (diluted) | 158.3 | 69.0 | 51.4 | 47.4 | 41.8 | 37.9 | 31.5 | 28.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|